Professional Documents
Culture Documents
Algorithm close: find out more and tell us what you think C
Chest pain in the last 12 hours Chest pain 12–72 hours ago
Initial assessment
(see box 3)
ECG findings Troponin levels
Yes No
Yes B No C
Move to Diagnosis D < slide 8 Initial assessment
The person does not have regional ST-segment depression or deep T wave
inversion suggestive of NSTEMI or unstable angina
• Increase suspicion of an ACS if there are Q waves and T wave changes, even
without ST-segment changes. Consider following NICE clinical guideline on
unstable angina and NSTEMI if unstable angina or NSTEMI is likely
• Consider taking serial ECGs, reviewing previous ECGs and recording additional
leads
• Consider other life-threatening conditions (e.g. pulmonary embolism, aortic
dissection or pneumonia)
• Continue monitoring (box 2)
Yes No Uncertain
Continue
Treat according to • Reassess
monitoring (
local protocols for • If myocardial ischaemia suspected,
box 2)
STEMI or NICE see diagnosis of stable chest pain A
management of unsta • Use clinical judgement to decide on
ble angina / NSTEMI timing of further investigations
C
B
End of acute chest pain diagnosis algorithm. < slide 9 Regional ST-segment
Shortcut to contents page elevation or presumed LBBB?
• Offer a single loading dose of 300 mg aspirin and continue aspirin indefinitely
• Offer fondaparinux to patients without a high bleeding risk unless angiography is
planned within 24 hours
• Offer unfractionated heparin if angiography is likely within 24 hours
• Carefully consider choice and dose of antithrombin for patients with a high bleeding
risk (see box 11)
– Consider unfractionated heparin, with dose adjusted to clotting function, if
creatinine > 265 micromoles per litre
Use established scoring system such as GRACE (see box 10) to predict 6-month mortality
and assess risk of future adverse cardiovascular events 1. Assess bleeding risk (see box 11)
and pertinent comorbidity before considering treatments and at each stage of
management
Recurrent spontaneous
ischaemia? Yes
No
Coronary
Consider ischaemia testing angiography Discuss managem
Yes ent with interven
tional cardiologist
and cardiac surg
Conservative eon
Ischaemia demonstrated?
No management
•Consider stopping clopidogrel 5 days before CABG in patients with low risk of
adverse cardiovascular events
•Discuss with surgeon whether to continue clopidogrel before CABG in patients
with intermediate or higher risk of adverse cardiovascular events
• Offer clopidogrel as a treatment option for up to 12 months to people who have had an
NSTEMI, regardless of treatment.
• Balance potential reduction in ischaemic risk with risk of bleeding and consider:
– adding a GPI (eptifibatide or tirofiban), or
– bivalirudin as an alternative to the combination of a heparin plus a GPI if the patient is
not on fondaparinux or a GPI and angiography is scheduled within 24 hours of
admission
Continue
Offer coronary angiography (with follow-on PCI if indicated) within 96 hours of first
admission unless contraindicated. Perform as soon as possible if patient is clinically
unstable or at high ischaemic risk
Conservative
Percutaneous coronary Coronary artery bypass
management intervention (PCI) grafting (CABG)
A B C
•Consider stopping clopidogrel 5 days before CABG in patients with low risk of
adverse cardiovascular events
•Discuss with surgeon whether to continue clopidogrel before CABG in patients
with intermediate or higher risk of adverse cardiovascular events
Shortcut to
management of stable a Return to slide 27 Stable angina is suspected
ngina
Implementing NICE Guidance www.nice.org.uk 28
Stable chest pain
Estimated likelihood of
CAD is less than 10%
Offer diagnostic testing (see boxes below) if stable angina cannot be confirmed or
excluded
Yes / No / Uncertain
Uncertain Yes No
Offer non-invasive functional imaging ( Investigate other
Treat as stable
box 8) causes of chest
angina
pain1
Yes No
Treat as stable Investigate other causes
angina of chest pain1
Yes No
Shortcut to
Return to slide 30 containing all risk classifications management of stable an
gina
Implementing NICE Guidance www.nice.org.uk 33
Stable chest pain – diagnostic testing
No Yes
A B
No Yes
Yes No
Reversible myocardial ischaemia?
Yes No
Shortcut to diagnosis of stable chest pain < slide 30 estimated likelihood of CAD 10−90%
• Do not offer a third anti-anginal drug if stable angina is controlled with two anti-
anginal drugs.
• Consider adding a third anti-anginal drug only when:
– two anti-anginal drugs do not satisfactorily control symptoms and
– the person is waiting for revascularisation or revascularisation is not considered
appropriate or acceptable.
• Decide which drug based on comorbidities, contraindications, the person’s preference
and drug costs.
Yes A No B
If either a beta blocker or calcium channel blocker does not satisfactorily control
symptoms, consider the other option (that is, calcium channel blocker or beta
blocker) or consider both drugs together1
A
• Do not offer a third anti-anginal drug if stable angina is controlled with two anti-
anginal drugs.
• Consider adding a third anti-anginal drug only when:
– two anti-anginal drugs do not satisfactorily control symptoms and
– the person is waiting for revascularisation or revascularisation is not considered
appropriate or acceptable.
• Decide which drug based on comorbidities, contraindications, the person’s
preference and drug costs.
Yes A No B
Yes A No B
• If stable angina does not respond to drug treatment and/or revascularisation, re-
evaluate. This may include:
– exploring the person’s understanding of their condition and the impact of
symptoms on quality of life
– reviewing the diagnosis and considering non-ischaemic causes of pain
– reviewing drug treatment and considering future drug treatment and
revascularisation options
– acknowledging the limitations of further treatment
– explaining how the person can manage their pain themselves
– specific attention to the role of psychological factors in pain
– developing skills to modify cognitions and behaviours associated with pain.
• Consider cardiac syndrome X in people with angiographically normal coronary
arteries and continuing anginal symptoms:
– continue drug treatment for stable angina if symptoms improve
– do not routinely offer drugs for secondary prevention of cardiovascular disease.
•Include:
–exacerbations of pain and/or other symptoms
–pulse and blood pressure
–heart rhythm
–oxygen saturation by pulse oximetry
–repeated resting 12-lead ECGs
–checking pain relief is effective.
•Include:
–exacerbations of pain and/or other symptoms
–pulse and blood pressure
–heart rhythm
–oxygen saturation by pulse oximetry
–repeated resting 12-lead ECGs
–checking pain relief is effective.
•Include:
–exacerbations of pain and/or other symptoms
–pulse and blood pressure
–heart rhythm
–oxygen saturation by pulse oximetry
–repeated resting 12-lead ECGs
–checking pain relief is effective.
•Include:
–exacerbations of pain and/or other symptoms
–pulse and blood pressure
–heart rhythm
–oxygen saturation by pulse oximetry
–repeated resting 12-lead ECGs
–checking pain relief is effective.
•Include:
–exacerbations of pain and/or other symptoms
–pulse and blood pressure
–heart rhythm
–oxygen saturation by pulse oximetry
–repeated resting 12-lead ECGs
–checking pain relief is effective.
•Include:
–exacerbations of pain and/or other symptoms
–pulse and blood pressure
–heart rhythm
–oxygen saturation by pulse oximetry
–repeated resting 12-lead ECGs
–checking pain relief is effective.
Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least
one value above the 99th percentile of the upper reference limit, together with
evidence of myocardial ischaemia with at least one of the following:
• symptoms of ischaemia
• ECG changes indicative of new ischaemia (new ST-T changes or new LBBB)
• development of pathological Q wave changes in the ECG
• imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality2
Clinical history
•Record:
– age and sex
– pain characteristics, factors provoking and relieving the pain
– associated symptoms
– history of cardiovascular disease
– cardiovascular risk factors.
Physical examination
•Identify cardiovascular risk factors.
•Look for signs of other cardiovascular disease.
•Exclude:
– non-coronary causes of angina (e.g. severe aortic stenosis, cardiomyopathy)
– other causes of chest pain.
•Full clinical history (including age, previous MI, previous PCI or CABG)
•Physical examination (including blood pressure and heart rate)
•Twelve-lead resting ECG
•Blood tests (such as troponin I or T, creatinine, glucose and haemoglobin)
•Advancing age
•Known bleeding complications
•Renal impairment
•Low body weight
•Advancing age
•Known bleeding complications
•Renal impairment
•Low body weight
Do not:
•exclude people from treatment based on their age alone
•investigate or treat symptoms differently based on gender or ethnic
group
•offer vitamins or fish oil. Inform people there is no evidence that they
help stable angina.
•offer transcutaneous electrical nerve stimulation (TENS), enhanced
external counterpulsation (EECP) or acupuncture to manage stable
angina.
•Advise people:
–how to administer short-acting nitrates
–to use immediately before planned exercise or exertion
–side-effects such as flushing, headache and light-headedness may occur
–to sit down or hold on to something if feeling light-headed.
•Consider the relative risks and benefits of CABG and PCI using a systematic
approach to assess severity and complexity of coronary disease and other
relevant clinical factors and comorbidities.
•Consider the relative risks and benefits of CABG and PCI using a systematic
approach to assess severity and complexity of coronary disease and other
relevant clinical factors and comorbidities.
•Consider the relative risks and benefits of CABG and PCI using a systematic
approach to assess severity and complexity of coronary disease and other relevant
clinical factors and comorbidities.
Next slide
Next slide
Clinical assessment:
Acute coronary syndrome No current chest pain
• Confirmed CAD
suspected – management – management and
• Non-anginal chest pain – stable angina not suspected
and referral referral
• Stable angina suspected
Acute chest pain assessment: Diagnosis of stable angina in people with suspected stable angina
• ECG findings when estimated likelihood of coronary artery disease:
• Tropinin results - is more than 90% - is less than 10% - is 10−90%
Early management of unstable angina or NSTEMI Medical management of stable angina if:
• Symptoms not controlled on BB or CCB
• Both BB and CCB are contraindicated or not tolerated
Management of people with Management of people with • BB or CCB are contraindicated or not tolerated
low 6-month mortality risk: high 6-month mortality risk
• Medication • Medication PCI CABG
• PCI • PCI
• CABG • CABG Further management if symptoms do not respond to medical
treatment or revascularisation